Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma
2016 (English)Article in journal (Other academic) Submitted
The treatment of diffuse large B-cell lymphoma (DLBCL) has improved during the last decades significantly; still drug resistance remains a major cause of treatment failure warranting further investigations to identify potential targets and to develop novel drugs. Proteasome inhibitors selectively kill cancer cells and the proteasome is an attractive therapeutic target in oncology. In the present study tumour material from 92 patients with DLBCL treated with either R-CHOP like (n=69) or CHOP like (n=23) regimens were stained for possible targets of proteasome inhibitors. The deubiquitinases (DUBs) of the proteasome; ubiquitin carboxyl-terminal hydrolase L5 (UCHL5) and ubiquitin specific peptidase 14 (USP14) was detected in the cytoplasm of the tumour cells in 77% and 74% of the cases, respectively. The findings in this study suggest that UCHL5 and/or USP14 should be further evaluated as new targets for proteasome inhibitors in DLBCL.
Place, publisher, year, edition, pages
proteasome inhibitors, UCHL5, USP14
Medical and Health Sciences Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-280542OAI: oai:DiVA.org:uu-280542DiVA: diva2:911147